Search Results

Press Releases

Protagenic Therapeutics Announces Pricing of Private Placement for Aggregate Gross Proceeds of $1.275 Million

October 29, 2024

·

3 min read

Business

Protagenic Therapeutics Reports Fourth Quarter and Full Year 2023 Results

Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a leader in biopharmaceutical innovation, today provided a corporate update and reported financial results for the fourth quarter and full year 2023.

April 1, 2024

·

7 min read

Business

Protagenic Therapeutics Schedules First Q4 and FY 2023 Earnings Call

Protagenic Therapeutics, Inc., a biopharmaceutical innovator, announced that the Company plans to hold its first investor earnings call to discuss the results contained in its FY 2023 Form 10K, which it plans to file that day, and its outlook for FY 2024.

March 25, 2024

·

2 min read

Drug Development

Protagenic Therapeutics Achieves First Clinical Safety Milestone with its Novel Neuropeptide for the Potential Treatment of Stress-Related Disorders

Protagenic Therapeutics, Inc. announced a step forward in its mission to address stress-related neuro-psychiatric disorders.

February 13, 2024

·

3 min read

Drug Development

Protagenic Therapeutics’ Stress-Regulating Peptide Demonstrates Exceptional Safety in Single Dose Portion of Phase I Trial, Paving the Way for Next Steps Toward Potential Breakthrough Treatments in Stress Related Neuropsychiatric Disorders

Protagenic Therapeutics, Inc., a leader in biopharmaceutical innovation, announced the complete safety data set from the single dose portion of its Phase 1 trial involving PT00114, its synthesized version of a natural stress-regulating brain peptide.

May 22, 2024

·

2 min read

Genetown

New Capital Strengthens ProtaGene’s Advanced Analytical Leadership in the Biologics and Cell and Gene Therapy Markets

ProtaGene, a leading global contract research organization dedicated to advanced analytics for biologics and cell and gene therapies, announced additional investment from Ampersand Capital Partners.

November 20, 2023

·

3 min read

Pharm Country

Protagenic Therapeutics Announces Date of Annual Shareholder Meeting

Protagenic Therapeutics, Inc. a biopharmaceutical company focused on developing therapies to treat stress-related neurologic disorders, announced its FY 2022 annual shareholder meeting will be held Wednesday, December 13, 2023, at 10:00 am EST, for shareholders of record as of this coming Monday, October 16th.

October 13, 2023

·

3 min read

Business

ProtaGene Appoints New Scientific and Commercial Leadership to Support Evolving Needs of Biologic and Cell & Gene Therapy Innovators

ProtaGene, GmbH, a leading global contract research organization focused on advanced analytics in biologics and cell and gene therapy, announced today the appointment of Jennifer Chadwick, Ph.D., as Chief Scientific Officer and Owen Hitchins as Chief Commercial Officer.

January 31, 2023

·

3 min read

Business

ProtaGene Names Pharmaceutical Industry Leader Raymond Kaiser as Chief Executive Officer to Drive Next Stages of Growth

ProtaGene GmbH, a leading global contract research organization focused on advanced analytics in biologics and cell and gene therapy, announced today the appointment of Raymond Kaiser, Ph.D., as Chief Executive Officer.

September 21, 2022

·

3 min read

Business

Analytical Service Leaders in Biopharmaceutical and Gene Therapy Development Unify Operations and Re-brand as ProtaGene

Following the announced merger in July 2021, Protagen Protein Services GmbH, BioAnalytix, Inc., and GeneWerk GmbH announced their unified operations and re-brand as ProtaGene, a world-leading CRO partner for the biopharmaceutical and cell & gene therapy industries.

January 12, 2022

·

3 min read